PTIX_OUT_1 [2025-04-03 04:07:02 -0400] 3529 Bytes | 932 tokens | Cum: 932 tkns (11.65% of 8k)
==========================================================================

We need a winner today and it's already 4:07:01 AM on Thu Apr 03, 2025 -0400 ... So let's find out if Performance Technologies (PTIX) is going up or if it's going nowhere fast. So, I pulled together a bunch of data for you to look over real fast. It's at 0.5662 up from 0.227. Is there something here we can get excited about? Help me analyze.

--- COMPANY PROFILE ---
Company: Performance Technologies (PTIX)
IPO: 2003-10-31 (21 Years Ago)
Market Cap: $1,810,361
Shares Outstanding: 7,240,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Protagenic Therapeutics Inc is a biopharmaceutical company focused on the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. It provides treatments for mood, anxiety, depression, and neurodegenerative disorders by using peptide-based and brain-active therapeutics. The company's lead compound, PT00114, is a synthetic form of Teneurin Carboxy-terminal Associated Peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. It has also created a portfolio of novel neuropeptides that are in various stages of development and preclinical evaluation for the treatment of mood disorders.

Here's the first list of news for Performance Technologies:

C1 - Nov-05-24 08:12AM - Protagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
C2 - Oct-29-24 10:27AM - Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million
C3 - Jun-25-24 06:53AM - PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q1 2024
C4 - May-22-24 08:12AM - Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders
C5 - May-01-24 08:38AM - Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
C6 - Apr-17-24 08:42AM - Protagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston Summit
C7 - Apr-01-24 09:53PM - PTIX Stock Earnings: Protagenic Therapeutics Reported Results for Q4 2023
C8 - Apr-01-24 09:53PM 04:20PM - Protagenic Therapeutics Reports Fourth Quarter and Full Year 2023 Results

Prior AI Reports for PTIX:
1. 2025-04-02 – Score: 10 – Target: 0.5529 – Highs: 0.2552 / – / –
struggling-company-faces-mounting-financial-challenges
2. 2025-04-01 – Score: 10 – Target: 0.2600 – Highs: 0.2782 / 0.2552 / –
companys-financial-health-deteriorates-amid-negative-performance-trends

(Note: Highs = Same day / 2nd day / 3rd day)

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on Performance Technologies (PTIX)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

PTIX_OUT_3 [2025-04-03 04:07:05 -0400] 1098 Bytes | 264 tokens | Cum: 1198 tkns (14.97% of 8k)
==========================================================================

Showing C4 (chunk 1 of 7): C4:
**Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders**
Date: May-22-24 08:12AM
Source: (ACCESSWIRE)
URL: https://www.accesswire.com/viewarticle.aspx?id=866223

The first and only All-in-one subscription platform offering
all of your PR Distribution and Media Outreach Tools in one
single solution.Monthly & Annual Subscriptions.

Find & create journalist lists with the most up to date database in the industry.

Personalize and customize your pitch for maximum engagement.

Discover your brand, industry, and competitor mentions.

The first and only All-in-one subscription platform that offers you the ability
to manage all of your IR communications needs from a single
source.Explore our IR subscri

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PTIX_OUT_5 [2025-04-03 04:07:05 -0400] 380 Bytes | 87 tokens | Cum: 1341 tkns (16.76% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PTIX_OUT_7 [2025-04-03 04:07:08 -0400] 253 Bytes | 85 tokens | Cum: 1428 tkns (17.85% of 8k)
==========================================================================

Showing A1 (chunk 1 of 1): A1:
Document A1 not found. Only 0 articles available.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PTIX_OUT_9 [2025-04-03 04:07:08 -0400] 1002 Bytes | 300 tokens | Cum: 1773 tkns (22.16% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2023-03-23T17:11:21Z - Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
B2 - 2022-12-30T17:28:11Z - Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session
B3 - 2021-08-30T13:15:00Z - Protagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ET
B4 - 2021-08-17T11:45:00Z - Protagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business Update
B5 - 2021-07-23T20:21:00Z - Protagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical Trial
B6 - 2021-06-07T12:07:58Z - 12 Health Care Stocks Moving In Monday's Pre-Market Session

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PTIX_OUT_11 [2025-04-03 04:07:14 -0400] 1098 Bytes | 323 tokens | Cum: 2098 tkns (26.22% of 8k)
==========================================================================

Showing B1 (chunk 1 of 3): B1:
**Why Block Shares Are Trading Lower By Over 13%? Here Are Other Stocks Moving In Thursday's Mid-Day Session**Date: Unknown DateSource: Unknown SourceURL: https://www.benzinga.com/news/23/03/31479420/why-block-shares-are-trading-lower-by-over-13-here-are-other-stocks-moving-in-thursdays-mid-day-sessGainers

DiamondHead Holdings Corp. (NASDAQ: DHHC) shares jumped 104.2% to $21.15. DiamondHead entered into convertible note purchase agreement dated March 21, 2023.
Boxed, Inc. (NYSE: BOXD) gained 59.1% to $0.2862 after gaining around 50% on Wednesday. Boxed recently said it is evaluating potentially filing for relief under the U.S. Bankruptcy Code and other strategic alternatives.
ZyVersa Therapeutics, Inc. (NASDAQ: ZVSA) shares climbed 36.8% to $2.16. ZyVersa Therapeutics recently reported new employment inducement grants under Nasdaq Listing Rule 5635(c)(4).
CXApp Inc. (NASDAQ: CXAI)

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PTIX_OUT_13 [2025-04-03 04:07:15 -0400] 1079 Bytes | 239 tokens | Cum: 2464 tkns (30.80% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes included at the...

S2 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes included at the...

S3 - 2025-03-31 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes included at the...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PTIX_OUT_15 [2025-04-03 04:07:16 -0400] 1098 Bytes | 229 tokens | Cum: 2695 tkns (33.69% of 8k)
==========================================================================

Showing S1 (chunk 1 of 6): S1:
Item 7. Managements Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes included at the end of this report. This discussion and other parts of this report contain forward-looking statements that involve risks and uncertainties such as statements of our plans, objectives, expectations and intentions. As a result of many factors, including those factors set forth in the Risk factors section of this report, our actual results could differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

##TABLE_START 42 ##TABLE_END

##TABLE_START ##TABLE_END

The discussion and analysis of our financial condition and results

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PTIX_OUT_17 [2025-04-03 04:07:16 -0400] 1098 Bytes | 223 tokens | Cum: 2920 tkns (36.50% of 8k)
==========================================================================

Showing S1 (chunk 2 of 6): of operations are based on Protagenics financial statements, which Protagenic has prepared in accordance with U.S. generally accepted accounting principles. The preparation of these financial statements requires Protagenic to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, Protagenic evaluates such estimates and judgments, including those described in greater detail below. Protagenic bases its estimates on historical experience and on various other factors that Protagenic believes are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PTIX_OUT_19 [2025-04-03 04:07:20 -0400] 1098 Bytes | 214 tokens | Cum: 3136 tkns (39.20% of 8k)
==========================================================================

Showing S1 (chunk 3 of 6): from other sources. Actual results may differ from these estimates under different assumptions or conditions.

We expect to continue to incur significant expenses and minimal positive net cash flows from operations or negative net cash flows from operations for the foreseeable future, and those expenses and losses may fluctuate significantly from quarter-to-quarter and year-to-year. We anticipate that our expenses will fluctuate substantially as we:

##TABLE_START continue our ongoing preclinical studies, clinical trials and our product development activities for our pipeline of product candidates; seek regulatory approvals for any product candidates that successfully complete clinical trials; continue research and preclinical development and initiate clinical trials of our other product candidates; seek to discover and develop additional product candidates either internally or in part

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PTIX_OUT_21 [2025-04-03 04:07:29 -0400] 4019 Bytes | 1147 tokens | Cum: 4379 tkns (54.74% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+--------------------+-----------------------+-----------------------+-------------------+
| Volume: 13,438,588 | Perf Month: -38.33% | Option/Short: No / No | Sales Y/Y TTM: - |
+--------------------+-----------------------+-----------------------+-------------------+
| Avg Volume: 2.08M | Perf Quarter: -57.74% | Short Float: 2.85% | ROE: -236.06% |
+--------------------+-----------------------+-----------------------+-------------------+
| Rel Volume: 6.45 | Index: - | Short Ratio: 0.09 | ROI: -545.36% |
+--------------------+-----------------------+-----------------------+-------------------+
| RSI (14): 42.27 | Market Cap: 1.71M | Short Interest: 0.19M | Sales Surprise: - |
+--------------------+-----------------------+-----------------------+-------------------+
| ATR (14): 0.04 | Shs Outstand: 7.24M | Beta: - | EPS Surprise: - |
+--------------------+-----------------------+-----------------------+-------------------+
| SMA20: -14.52% | Shs Float: 6.52M | Sales Q/Q: - | P/E: - |
+--------------------+-----------------------+-----------------------+-------------------+
| SMA50: -24.74% | Inst Own: 5.18% | Sales past 5Y: 0.00% | Earnings: - |
+--------------------+-----------------------+-----------------------+-------------------+
| SMA200: -59.96% | Insider Own: 13.43% | Employees: 3 | |
+--------------------+-----------------------+-----------------------+-------------------+
| Perf Week: -13.69% | Insider Trans: 0.00% | Debt/Eq: 0.00 | |
+--------------------+-----------------------+-----------------------+-------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -5647785.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 0.227
Average Volume: 5470609.27
30-Day High: 0.3681
30-Day Low: 0.1951

[Detailed Financials: Q3 2024]
- Total Assets: $1,508,327.0
- Total Liabilities: $789,320
- Total Equity: $719,007
- Current Assets: $1,422,709.0
- Current Liabilities: $789,320

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.14

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $0

[Detailed Financials: Q2 2024]
- Total Assets: $1,467,077.0
- Total Liabilities: $674,559
- Total Equity: $792,518
- Current Assets: $1,368,888.0
- Current Liabilities: $674,559

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -0.36

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

PTIX_OUT_23 [2025-04-03 04:07:31 -0400] 676 Bytes | 167 tokens | Cum: 4746 tkns (59.33% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

PTIX_IN_25 [2025-04-03 04:07:31 -0400] 126 Bytes | 29 tokens | Cum: 4803 tkns (60.04% of 8k)
==========================================================================

====================================
[2025-04-03 04:07:31] # Analysis Completed
Elapsed Time: 30.14 seconds